ADHD symptoms[br-d]have range.
So does Simtriyo.
Simtriyo is the first-and-only norepinephrine-dopamine-serotonin reuptake inhibitor (NDSRI) and CNS stimulant for the treatment of ADHD in adults and children aged 6 and up, designed to help your patients manage a wide range of challenges.1
Limitations of Use: Simtriyo is not recommended in pediatric patients younger than 6, due to higher incidence of weight loss than patients 6 and older, or in pediatric patients weighing less than 20 kg due to lack of data and risk of weight loss.
Please see FULL PRESCRIBING INFORMATION, including BOXED WARNINGS.
Please see FULL PRESCRIBING INFORMATION, including BOXED WARNINGS.
Actor portrayal
ADHD isn’t just one challenge—which calls for a treatment equipped to take on all the ways ADHD can show up.
Explore the many ways ADHD can impact patients
56
72
0
HOW SIMTRIYO WORKS
center
text-brand-orange
font-weight-extrabold
site-eyebrow
4
4
0
Treat with the trio
center
site-jumbo
16
16
0
A first-in-class treatment that targets 3 neurotransmitters—norepinephrine, dopamine, and serotonin—and is a CNS stimulant.1 The mechanism of action of Simtriyo in the treatment of ADHD is unclear; however, its efficacy could be mediated through its activity as an NDSRI.
text-center
text-brand-navy
font-weight-medium
size-medium
link-underline-red
align-center
700px
32
32
0
16
16
0
CNS=central nervous system.
text-center
text-brand-navy
font-weight-medium
size-website-caption
link-underline-red
align-center
700px
104
72
0
tan
-255px
A first-in-class treatment [br-m]for ADHD
Simtriyo is intended to address a wide range of symptoms in adult and pediatric patients by targeting norepinephrine, dopamine, and serotonin. It’s also a [br-m]CNS stimulant.
Adults
Explore the results of 2 clinical trials in adults with ADHD.
Adult data
Adolescents
Explore the results of a clinical trial in adolescents aged 13 though 17 with ADHD.
Adolescent data
Children
Explore the results of a clinical trial in children aged 6 through 12 with ADHD.
Children’s data
20
20
20
true
green
SAFETY & TOLERABILITY
Built with the patient in mind
button
right
full-width
104
72
0
eop
horizontal
blue
We’re on your [br-d]patients’ team
See our support and savings resources to help your appropriate patients get started on Simtriyo.
Explore savings & support
Actor portrayal
light
center
horizontal
blue
Sign up for Simtriyo email updates
Get notified of news, receive downloadable resources, and more.
sign up
Actor portrayal
dark
center
40
40
0
default
REFERENCE
- Simtriyo Prescribing Information. Otsuka America Pharmaceutical, Inc. 2026.